Furthermore, the monoclonal antibody DKN-01, which targets DKK1, was evaluated in combination with gemcitabine and cisplatin in a phase I clinical trial in patients with HCC and cholangiocarcinoma (NCT02375880) (6). Here, DKK1 is linked to cholangiocarcinoma.